Ajinomoto Bio-Pharma to Acquire Joint Venture Granules OmniChem in India
The transaction will reach completion during the fourth quarter of 2019.
Ajinomoto Bio-Pharma Services, a biopharmaceutical contract development and manufacturing services company, announced on Aug. 29, 2019 that it will purchase 50% ownership interest in its Visakhapatnam, India, joint venture, Granules OmniChem Private Limited (GOC) from its joint venture partner, Granules India Limited. The transaction is expected to close during the fourth quarter of 2019. The financial details were not disclosed.
The GOC venture by Ajinomoto OmniChem N.V. and Granules India Limited was originally established in 2011, according to a company press release. The companies worked to provide small-molecule intermediates and API manufacturing to the pharmaceutical industry.
“GOC has been a well-run producer of high-quality API since its formation, which was designed, constructed and is managed based on our Belgian sites’ GMP operating standards and quality systems,” said David Enloe, CEO, Ajinomoto Bio-Pharma Services, in the press release. “This allows us to provide a seamless experience for our clients as they continue to deepen their partnerships with us on key programs in their product pipelines.”
“We are extremely pleased to now be a fully integrated member of Aji Bio-Pharma,” said K.V.V. Raju, CEO, Granules OmniChem Pvt. Ltd., in the press release. “As an official part of this CDMO [contract development and manufacturing organization], our team can further enhance Aji Bio-Pharma’s ability to deliver value to our customers and contribute to the improving the health of humankind mission.”
Source: Ajinomoto Bio-Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
